Tropical Diseases, Travel Medicine and Vaccines最新文献

{"title":"GenoDense-Net: unraveling the genomic puzzle of the global pathogen.","authors":"Shivendra Dubey, Sakshi Dubey, Kapil Raghuwanshi, Pranshu Pranjal, Sudheer Kumar","doi":"10.1186/s40794-025-00267-y","DOIUrl":"10.1186/s40794-025-00267-y","url":null,"abstract":"<p><p>The respiratory system of humans is impacted by infectious and deadly illnesses like COVID-19. Early identification and diagnosis of this type of illness is essential to stop the infection from spreading further. In the present research, we presented a technique for determining the condition using COVID-19's current genome sequences employing the DenseNet-16 framework. We operated a network of already trained neurons before using a transfer learning method to prepare it according to our dataset. Additionally, we preprocessed the collected information using the NearKbest interpolation approach; then, we utilized Adam Optimizer to optimize our findings. Compared with special deep learning models like ResNet-50, VGG-19, AlexNet, and VGG-16, our approach produced an accuracy of 99.18%. The model was deployed on a platform with GPU support, which greatly decreased training time. Dataset size and the requirement for further validation are two of the study's limitations, despite the encouraging results. The current research showed how a deep learning approach may be useful to categorize the genome sequence of infectious disease like COVID-19 using the suggested GenoDense-Net architecture. The next step in this research project is conducting investigations in the clinic.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"32"},"PeriodicalIF":2.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imported plasmodium ovale malaria from Côte d'Ivoire: a case report.","authors":"Juan David Plata-Puyana, Johanna Katherine Vanegas Beltrán, María Cristina Martínez-Ávila","doi":"10.1186/s40794-025-00253-4","DOIUrl":"10.1186/s40794-025-00253-4","url":null,"abstract":"<p><strong>Background: </strong>Malaria remains a significant global health issue, with an estimated 263 million cases and 597,000 deaths reported in 2023. Plasmodium ovale, although less common than P. falciparum and P. vivax, presents diagnostic challenges due to its morphological resemblance to P. vivax and its ability to form latent liver-stage hypnozoites, leading to delayed relapses.</p><p><strong>Case presentation: </strong>This case report describes a 29-year-old male who presented with fever, chills, and myalgia upon returning to Bogotá, Colombia, after a three-month stay in Côte d'Ivoire, Africa. Initial microscopy misidentified the parasite as P. falciparum, leading to diagnostic uncertainty. Polymerase chain reaction (PCR) confirmed P. ovale infection, emphasizing the critical role of molecular diagnostics in differentiating malaria species. The patient was treated with chloroquine and primaquine for radical cure. Initially, the patient received artemether-lumefantrine empirically. Once the diagnosis of P. ovale was confirmed, he was switched to chloroquine followed by primaquine (15 mg base daily for 28 days) as radical cure. G6PD testing was not available in our setting, but the patient was monitored clinically and tolerated the medication without adverse effects.</p><p><strong>Conclusions: </strong>Given that P. ovale is not endemic to Colombia, increased awareness among clinicians is necessary for accurate diagnosis and management of imported malaria cases. Enhanced surveillance and advanced diagnostic techniques are essential to prevent misdiagnosis and ensure appropriate treatment.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"31"},"PeriodicalIF":2.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of serum electrolytes and kidney function among untreated malaria (Plasmodium falciparum) patients in health centers, Konso zone, South Ethiopia.","authors":"Bachaw Basire, Belayhun Kibret, Kibru Kifle, Freshet Assefa","doi":"10.1186/s40794-025-00265-0","DOIUrl":"10.1186/s40794-025-00265-0","url":null,"abstract":"<p><strong>Background: </strong>Malaria is a major health problem around the world. Plasmodium falciparum (P. falciparum) is the species that is most commonly associated with the severe and complicated forms of malaria, especially in tropical and subtropical areas, including Ethiopia. One of the complications of malaria is its impact on kidney and electrolyte levels. The objectives of the study were to assess the kidney function and serum electrolyte levels among untreated malaria patients infected with P. falciparum.</p><p><strong>Methodology: </strong>A case-control study that enrolled a total of 108 participants (54 with confirmed untreated P. falciparum malaria as a case and 54 were non-malaria as a control). Participants in the study were included based on systematic random sampling technique. Data were collected using questionnaires administered by interviewers. 5 ml of blood samples were collected to investigate kidney function such as creatinine and urea, as well as serum electrolytes such as sodium ion (Na⁺) and potassium ion (K⁺), using a chemistry automated analyzer. Data were analyzed using the statistical package for social science (SPSS) version 27. P < 0.05 was considered statistically significant at a 95% confidence interval (CI).</p><p><strong>Result: </strong>The study subjects were comprised of 52 (48.1%) men and 56 (51.9%) women. The mean age for the case group and the control group was 26.85 ± 8 and 27.17 ± 7.17 years old, respectively. The result showed a statistically significant (P < 0.05) increase in serum creatinine and urea level in the case group (1.32 ± 0.29 mg/dL and 39.8 ± 8.34 mg/dL) compared with the control group (0.92 ± 0.32 mg/dL and 25.78 ± 7.97 mg/dL), respectively. The serum levels of Na⁺ and K⁺ were significantly (P < 0.05) decreased in the case group (132.15 ± 3.96 mmol/L and 3.44 ± 0.40 mmol/L) as compared to the control group (137.11 ± 3.11 mmol/L and 3.94 ± 0.39 mmol/L), respectively.</p><p><strong>Conclusion: </strong>Malaria has a significant impact on kidney function (creatinine and urea) and serum electrolytes (Na⁺ and K⁺). This may indicate that malaria is the determinant factor for developing kidney dysfunction and serum electrolyte imbalance. Hence, we recommend routine evaluation of these parameters in malaria-infected individuals.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"29"},"PeriodicalIF":2.2,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging role of Imatinib in malaria management: a review of evidence and future directions.","authors":"Victor Oluwatomiwa Ajekiigbe, Chidera Stanley Anthony, Ikponmwosa Jude Ogieuhi, Jonathan Oluwafemi Adeola, Peace Uchechi Bassey, Pelumi Gbolagade-Jonathan, Stephen Olaide Aremu, Akintunde Abisoye Omoleke, Ifeoluwa Sandra Bakare, Adedoyin Veronica Babalola","doi":"10.1186/s40794-025-00257-0","DOIUrl":"10.1186/s40794-025-00257-0","url":null,"abstract":"<p><strong>Background: </strong>Malaria still remains one of the leading causes of death, especially in Africa, with one of the major struggles associated with eradication being resistance to antimalarial medications. Imatinib, a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia, has emerged as a potential pharmacological approach for malaria management.</p><p><strong>Methods: </strong>This review synthesizes studies from the inception of the databases of PubMed, Scopus, Google Scholar, Cochrane, Web of Science, and Embase to February 2025, identifying key clinical trials and invitro studies conducted to assess the efficacy and safety of Imatinib in malaria.</p><p><strong>Results: </strong>With varying sample sizes, dosage and follow-up data, the studies reported a decline in parasite density, pyrexia, parasite growth inhibition, and synergism with other anti-malarial medications like Artesunate. Across the nine (9) studies reviewed, Imatinib showed a favorable safety profile with no adverse drug-related events reported.</p><p><strong>Conclusions: </strong>We discuss the potential advantages and challenges of repurposing Imatinib for treating malaria, its pharmacokinetic profile, and its use in other patient populations, such as children and pregnant women. Future studies should focus on randomized controlled trials with larger sample sizes and possible combination therapies with other antimalarial medications.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"28"},"PeriodicalIF":2.2,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.","authors":"Thanutcha Mahathumnuchok, Vanlaya Koosakulchai, Pasuree Sangsupawanich, Porntip Intapiboon, Pornruedee Rachatawiriyakul, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Araya Yuenyongviwat","doi":"10.1186/s40794-025-00266-z","DOIUrl":"10.1186/s40794-025-00266-z","url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reactions (HSR) to the COVID-19 vaccine have been reported. Despite these reactions, revaccination remains essential.</p><p><strong>Objective: </strong>This study aims to explore the potential outcomes of COVID-19 revaccination in individuals with prior vaccine-related adverse reactions.</p><p><strong>Methods: </strong>A retrospective study was employed with a sample of 225 patients, with HSR regarding COVID-19 vaccines, who were referred to a university hospital. Demographic data, vaccine types and HSR were collected.</p><p><strong>Results: </strong>Seventy-seven percent (175/225) of patients were revaccinated post HSR. Out of the 175 patients, 57.1%, 34.2% and 8.5% had a history of HSR in connection to inactivated vaccines, viral vector vaccines, and mRNA vaccines, respectively. Sixty percent were revaccinated with the same type of vaccine and 63.4% received antihistamines and/or anti-leukotriene premedication. After revaccination, 89.1% did not have adverse reactions, while 10.9% had mild reactions. When comparing patients who experienced HSR following COVID-19 revaccination with those who did not exhibit reactions, a significant association among patients with revaccination adverse effects were a revaccination with inactivated vaccines; Sinovac-CoronaVac (P < 0.001), a history of any allergic diseases (P < 0.001) and underlying allergic rhinitis (P = 0.003). Premedication or change of vaccine type did not have an effect to the rate of adverse reactions reported post revaccinations.</p><p><strong>Conclusions: </strong>In this study, COVID-19 revaccination in patients with a history of COVID-19 vaccine-related HSRs was generally safe, with most patients tolerating it well. However, individuals with underlying allergic conditions, particularly allergic rhinitis, exhibited a higher incidence of mild reactions, especially following revaccination with an inactivated vaccine.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"30"},"PeriodicalIF":2.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue fever in Bangladesh: rising trends, contributing factors, and public health implications.","authors":"Ikponmwosa Jude Ogieuhi, Mohamed Mustaf Ahmed, Safayet Jamil, Olalekan John Okesanya, Bonaventure Michael Ukoaka, Gilbert Eshun, Jerico Bautista Ogaya, Don Eliseo Lucero-Prisno Iii","doi":"10.1186/s40794-025-00251-6","DOIUrl":"10.1186/s40794-025-00251-6","url":null,"abstract":"","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"26"},"PeriodicalIF":2.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-step ahead: evaluating the efficacy of single-visit rabies pre-exposure prophylaxis against conventional multi-visit protocol: a randomized non-inferiority clinical trial.","authors":"Aman Dev Singh, Simmi Oberoi, Rohit Batish, Kanwardeep Singh, Maninder Kaur, Shailpreet Kaur Sidhu, Avneet Kaur, Prabhasees Singh","doi":"10.1186/s40794-025-00262-3","DOIUrl":"10.1186/s40794-025-00262-3","url":null,"abstract":"","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"25"},"PeriodicalIF":2.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cost-benefit analysis of using wastewater monitoring to guide typhoid vaccine campaigns.","authors":"Aparna Keshaviah, Agha Ali Akram, Dheeya Rizmie, Ian Raxter, Rezaul Hasan, Ziaur Rahman, Afroza Jannat Suchana, Farjana Jahan, Aninda Rahman, Mahbubur Rahman, Mahbubur Rahman, Megan B Diamond, Anthony Louis D'Agostino","doi":"10.1186/s40794-025-00260-5","DOIUrl":"10.1186/s40794-025-00260-5","url":null,"abstract":"<p><strong>Introduction: </strong>Enteric diseases are a leading cause of mortality in developing countries, yet are highly preventable. Typhoid vaccines remain underutilized, and diagnostic capacity constraints impede treatment and prevention. Wastewater monitoring could provide a more accurate picture of disease burden if detection and quantification of Salmonella Typhi in wastewater are advanced. To motivate why countries should invest to improve wastewater testing methods, we conducted a cost-benefit analysis, quantifying the value this approach could yield.</p><p><strong>Methods: </strong>We estimated benefits that could accrue if wastewater data informed the early launch of a theoretical typhoid vaccine campaign in Cox's Bazar, Bangladesh. After empirically estimating the lead-time advantage of wastewater data over clinical data to flag case upticks, we simulated changes in case counts from a 1- to 14-day early campaign launch, using ordinary differential equation modeling. We quantified benefits resulting from averted cases (from preserved caregiver time, school days, and wages), hospitalizations (from savings to public funds), and deaths (using the value of statistical life). We then calculated how cumulative benefits, costs, and the ratio of the two varied by campaign launch timing scenario over a five-year period.</p><p><strong>Results: </strong>Wastewater concentrations of Salmonella Typhi upticked up to 13 days before case counts. Cumulative benefits varied by year and launch timing. With a 13-day early launch, every $100 spent on wastewater monitoring could yield $295 in societal benefits by year 5. Cumulative benefits roughly equaled cumulative costs with a 5-day early launch and outweighed costs when the campaign was launched even earlier.</p><p><strong>Conclusion: </strong>If wastewater data can be advanced to reliably provide early warnings of new typhoid outbreaks, governments could reap large benefits that more than justify spending on program implementation. Our findings could generalize to other high-aid countries that, like Bangladesh, experience routine enteric disease outbreaks and have strong operational networks.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"24"},"PeriodicalIF":2.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, laboratory features and treatment outcomes of patients infected with Fasciola in Northern Vietnam, 2019-2023.","authors":"Nguyen Kim Thu, Phan Khac Dong Duong, Tran Huy Tho, Le Van Duyet","doi":"10.1186/s40794-025-00261-4","DOIUrl":"10.1186/s40794-025-00261-4","url":null,"abstract":"<p><strong>Background: </strong>Vietnam experiences a significant occurrence of fascioliasis infection, largely due to the common practice of consuming raw vegetables. Diagnosing the fascioliasis infection remains difficult, and patients endure various long-term consequences. The purpose of this study is to describe the clinical and laboratory features, along with the treatment approaches for fascioliasis patients in Vietnam.</p><p><strong>Methods: </strong>The study included 31 patients diagnosed with fascioliasis in Northern Vietnam between 2019 and 2023. Blood ELISA testing, fresh stool microscopy, ultrasonography, and magnetic resonance imaging were all used to evaluate the patients. The patients received triclabendazole, and the efficacy of treatment was assessed three months later.</p><p><strong>Results: </strong>All patients infected with Fasciola reported having raw vegetables and exhibited typical clinical symptoms of right hypochondriac pain (61%), epigastric pain (58%), exhaustion, and anorexia (42%). All patients presented with a hepatic lesion, with an average abscess measuring of 5.5 ± 2.8 cm. Increased eosinophil levels were noted in 77% and 68% of the patients, whereas only 13%, 36%, and 19% showed decreased red blood cell counts, elevated white blood cell counts, and increased liver enzyme levels, respectively. Following three months of treatment with triclabendazole, 81% of patients achieved cure, while 19% (6 patients) remained uncured. The patients who did not respond to the initial treatment received an additional dose of triclabendazole (20 mg/kg body weight) and were monitored for another three months; all of these patients were cured.</p><p><strong>Conclusions: </strong>The functional symptoms associated with fascioliasis include right hypochondriac pain, epigastric pain, fatigue, anorexia, weight loss, and fever. However, observable physical symptoms such as enlarged liver, jaundice, and yellow eyes are uncommon. Patients may exhibit liver lesions and an increase in eosinophils, but they rarely present with elevated liver enzymes or anemia. Treatment using triclabendazole is highly effective; however, an additional dose of triclabendazole is necessary to reach optimal effectiveness.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"23"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive phenotypic and genotypic taxonomic review of Leishmania (Leishmania) poncei n. sp. (Kinetoplastea: Trypanosomatidae): a novel agent of cutaneous (non-ulcerated) and visceral leishmaniasis in Honduras, Central America.","authors":"Fernando Tobias Silveira, Gabriela V Araujo Flores, Carmen Maria S Pacheco, Wilfredo Sosa-Ochoa, Thiago Vasconcelos Dos Santos, Edivaldo Costa Sousa, Concepción Zúniga Valeriano, Vania Lucia da Matta, Claudia Maria C Gomes, Patrícia Karla Ramos, Luciana Vieira Lima, Marliane Batista Campos, Carlos Eduardo P Corbett, Márcia Dalastra Laurenti","doi":"10.1186/s40794-025-00264-1","DOIUrl":"10.1186/s40794-025-00264-1","url":null,"abstract":"<p><p>Non-ulcerated cutaneous leishmaniasis (NUCL) is an atypical clinical form of leishmaniasis first described, in 1988, by Ponce and collaborators, in Honduras, Central America, characterized by isolated or disseminated closed skin lesions appearing as papules, nodules, or infiltrated plaques, primarily in adolescents and young adults. Leishmania (L.) chagasi was then identified as the causal agent of both NUCL and American visceral leishmaniasis (AVL) in Honduras, though NUCL has been reported as more prevalent. However, due to the uncertain taxonomic classification of the NUCL-causing parasite, especially since L. (L.) chagasi has not been associated to this form of the disease in South America, this study conducted a comprehensive taxonomic review incorporating phenotypic (biological and clinical-immunopathological) and genotypic (genomic/molecular) analyses. Biologically, Honduran parasite-LPG does not have Gal (β1,4) Man (α1)-PO4 side chains common to all Leishmania LPGs. From a clinical-pathogenic perspective, NUCL is unique, it does not ulcerate like cutaneous leishmaniasis due to L. (L.) chagasi or L. (L.) infantum. Molecular findings showed that the Honduran parasite is more ancestral than all known viscerotropic Leishmania species, exhibited an unprecedented structural variation on chromosome 17 with the highest frequency of genomic SNPs, formed a distinct phylogenetic lineage, and displayed a homozygous SNP profile typical of a parental (non-hybrid) parasite. Building on these findings, a new species, Leishmania (Leishmania) poncei n. sp. (Kinetoplastea: Trypanosomatidae), is proposed in honor of Professor Carlos Ponce, who first described NUCL in Honduras. This study formally classifies L. (L.) poncei n. sp. as a novel Leishmania species responsible for both NUCL and AVL in Honduras, Central America.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"11 1","pages":"27"},"PeriodicalIF":2.2,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}